Monitoring Agency Report for the quarter ended on March 31, 2025
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma has filed the Monitoring Agency Report from CARE Ratings for its Rs. 3,000 crore QIP conducted in December 2024. The entire Rs. 2,900 crore earmarked for repaying Commercial Paper Series I was utilized (Rs. 2,900.03 crore, deviation under 10%). The Rs. 55 crore tagged for General Corporate Purposes was also redirected toward the same Commercial Paper repayment, as authorized by the Fund-Raising Committee. Of the Rs. 45 crore set aside for issue expenses, Rs. 42.54 crore has been spent, leaving Rs. 2.43 crore unutilized and parked in the QIP bank account. No material deviation from stated objects has been reported, and the funds deployment is on track.
This is a routine compliance filing confirming that the QIP proceeds have been used as disclosed — primarily to retire short-term commercial paper debt, which modestly reduces the company's leverage and interest cost. No negative surprises or deviations, so the filing is neutral to mildly positive for shareholders.